Close Menu

NEW YORK (GenomeWeb) – CRISPR Therapeutics announced today that it has raised an additional $38 million as part of a Series B Financing round.

The company said the funding round raised almost $140 million overall, with the first part of the financing being led by Vertex Pharmaceuticals and Bayer Global Investments, and the second, oversubscribed closing including new institutional investors and specialized healthcare funds such as Franklin Templeton Investments, New Leaf Venture Partners, and funds advised by Clough Capital Partners and Wellington Capital Management.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.